A New Assay for Thyrotropin Receptor Autoantibodies
- 1 October 2004
- journal article
- research article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 14 (10), 830-835
- https://doi.org/10.1089/thy.2004.14.830
Abstract
A new procedure for measuring patient serum thyrotropin receptor (TSHR) autoantibodies is described in which the autoantibodies inhibit binding of a human monoclonal thyroid stimulating antibody M22 (labeled with biotin) to TSHR-coated enzyme-linked immunosorbent assay (ELISA) plate wells. In the assay, M22-biotin binding is detected by addition of streptavidin peroxidase. The M22 based assay was more sensitive than a similar ELISA based on inhibition of TSH-biotin binding to TSHR coated wells with 1 U/L of NIBSC 90/672 giving approximately 35% inhibition in the M22-based system compared to approximately 15% inhibition in the TSH-based ELISA. This had an important impact on the precision of the 2 assays with the M22-based ELISA showing an interassay coefficient of variation (CV) of 10% at 1 U/L whereas the TSH-based ELISA had an interassay CV of 20% at 1 U/L. Analysis of sera from 307 control subjects without a diagnosis of Graves' disease indicated that only 2 (0.65%) gave inhibition of M22 binding values of greater than 10% (11% and 12% inhibition). In the case of sera from 108 patients with Graves' disease (treated and untreated) 103 (95%) gave inhibition of M22 binding values of 14% or greater. Receiver operating characteristic (ROC) plot analysis showed that 100% specificity for TSHR autoantibody detection in Graves' disease was obtained at 95% sensitivity for the M22-based ELISA and 89% sensitivity for the TSH-biotin–based ELISA. Inhibition of M22 binding to the TSHR was closely correlated to inhibition of TSH binding in the 108 Graves' sera (r = 0.99). However, inhibition of M22 binding was almost always greater resulting in improved sensitivity and precision.Keywords
This publication has 15 references indexed in Scilit:
- Thyroid-Stimulating Monoclonal AntibodiesThyroid®, 2002
- Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptorJCI Insight, 2002
- Epitope Mapping of TSH Receptor-Blocking Antibodies in Graves' Disease That Appear during PregnancyJournal of Clinical Endocrinology & Metabolism, 2001
- Hashimoto's Thyroiditis with Heterogeneous Antithyrotropin Receptor Antibodies: Unique Epitopes May Contribute to the Regulation of Thyroid Function by the AntibodiesJournal of Clinical Endocrinology & Metabolism, 2000
- The Interaction of TSH Receptor Autoantibodies with 125I-Labelled TSH ReceptorJournal of Clinical Endocrinology & Metabolism, 1999
- Second Generation Assay for Thyrotropin Receptor Antibodies Has Superior Diagnostic Sensitivity for Graves' DiseaseJournal of Clinical Endocrinology & Metabolism, 1999
- Autoantibodies to the Thyrotropin ReceptorEndocrine Reviews, 1988
- A RECEPTOR ASSAY FOR THE MEASUREMENT OF TSH RECEPTOR ANTIBODIES IN UNEXTRACTED SERUMClinical Endocrinology, 1984
- Preparation of125I-Labeled Receptor-Purified Graves' Immunoglobulins: Properties of Their Binding to Human Thyroid Membranes*Journal of Clinical Endocrinology & Metabolism, 1982
- Characterisation of long-acting thyroid stimulator γG binding proteinBiochimica et Biophysica Acta (BBA) - Protein Structure, 1971